TransMedics Group (NASDAQ:TMDX) Trading Up 3.7% – Here’s Why

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) traded up 3.7% during trading on Tuesday . The stock traded as high as $61.90 and last traded at $61.48. 585,065 shares were traded during trading, a decline of 44% from the average session volume of 1,052,683 shares. The stock had previously closed at $59.28.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on TMDX shares. Oppenheimer reaffirmed an “outperform” rating and issued a $125.00 price objective on shares of TransMedics Group in a research note on Tuesday, December 3rd. Canaccord Genuity Group reduced their price target on TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research report on Wednesday, November 20th. TD Cowen lowered their price objective on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research report on Monday, November 18th. Baird R W upgraded shares of TransMedics Group to a “strong-buy” rating in a research note on Tuesday, September 24th. Finally, Robert W. Baird lowered their price target on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, TransMedics Group has an average rating of “Moderate Buy” and an average target price of $122.70.

TransMedics Group Price Performance

The stock has a 50 day moving average price of $80.40 and a two-hundred day moving average price of $125.46. The company has a market capitalization of $2.07 billion, a PE ratio of 65.76 and a beta of 2.06. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). The business had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The business’s quarterly revenue was up 63.7% compared to the same quarter last year. During the same period last year, the business earned ($0.12) EPS. Equities analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Insider Buying and Selling at TransMedics Group

In related news, insider Tamer I. Khayal sold 1,084 shares of the company’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $86.40, for a total value of $93,657.60. Following the completion of the sale, the insider now owns 20,843 shares in the company, valued at $1,800,835.20. This represents a 4.94 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total value of $1,144,623.75. Following the completion of the sale, the chief executive officer now owns 61,643 shares in the company, valued at $8,180,642.53. The trade was a 12.27 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 16,459 shares of company stock worth $1,802,244 over the last ninety days. Corporate insiders own 7.00% of the company’s stock.

Institutional Trading of TransMedics Group

Hedge funds have recently made changes to their positions in the business. Amalgamated Bank boosted its holdings in shares of TransMedics Group by 6.7% during the 2nd quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock worth $168,000 after buying an additional 70 shares during the period. Harbour Capital Advisors LLC increased its stake in shares of TransMedics Group by 1.7% during the third quarter. Harbour Capital Advisors LLC now owns 4,841 shares of the company’s stock worth $760,000 after purchasing an additional 81 shares during the period. Signaturefd LLC lifted its holdings in TransMedics Group by 26.6% during the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after purchasing an additional 93 shares during the last quarter. Arizona State Retirement System grew its holdings in TransMedics Group by 2.1% in the 2nd quarter. Arizona State Retirement System now owns 9,158 shares of the company’s stock valued at $1,379,000 after buying an additional 186 shares in the last quarter. Finally, Venturi Wealth Management LLC lifted its holdings in shares of TransMedics Group by 33.7% during the third quarter. Venturi Wealth Management LLC now owns 869 shares of the company’s stock worth $136,000 after buying an additional 219 shares in the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.